EasyM: Blood-based MRD for MM

Rapid Novor EasyM is a non-invasive, blood-based MRD test for MM, tracking unique M-protein peptides via mass spectrometry for precise monitoring.

[EasyM: Blood-based MRD for MM @easym_test]

Heading into #ASCO25 we're happy to share our latest paper with the #myeloma community. Dr. Slade has been instrumental to helping EasyM develop its state-of-the art non-invasive #mmMRD assay and we look forward to the next !

EasyM is a CLIA certified LDT and not FDA approved

[FDA Oncology @FDAOncology]

NEWS: @US_FDA has approved a subcutaneous injection for multiple myeloma across various stages of treatment. https://t.co/W34DYQnnmk

[EasyM: Blood-based MRD for MM @easym_test]

Check out the latest @HealthTree interview with our Senior Scientist where they discuss our newest research on EasyM, our blood-based MRD test for multiple myeloma 🩸

Watch the interview to learn more 🎥 : https://t.co/HOML8FaoH1

EasyM is currently available for patients in the US and Canada.

#MultipleMyeloma #MRD #MM #Hematology #MMSM #EHA2026

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

Blood-based Mass Spectrometry MRD Testing for #Myeloma : EasyM | EHA 2026 #mmsm
https://t.co/xs86JUnqLr

[EasyM: Blood-based MRD for MM @easym_test]

🩸 Can a blood test help monitor myeloma after CAR T therapy?

New research suggests EasyM, a highly sensitive blood test, detects tiny amounts of myeloma protein after CAR T treatment without repeated bone marrow biopsies.

Find the poster and abstract here: https://t.co/1TOvTk70Sx

#MultipleMyeloma #MM #CART #MMSM #MRD

[EasyM: Blood-based MRD for MM @easym_test]

New research alert 📣 📰

Poster from Monash University presented at EHA 2026 compared the EasyM and EXENT blood tests for monitoring multiple myeloma.

The study found that EasyM detected lower levels of M-protein, particularly in patients with deep treatment responses, while showing strong overall correlation with EXENT.

Find the poster and abstract here: https://t.co/kAlnKtfV18

#EHA2026 #MM #MRD #MMSM #MultipleMyeloma

[EasyM: Blood-based MRD for MM @easym_test]

Reflecting on EHA 2026 💭

We're grateful for the opportunity to present two posters and connect with so many researchers, clinicians, and collaborators.

One of the highlights was discussing the growing role and importance of blood-based MRD monitoring in multiple myeloma. The thoughtful conversations, questions, and shared perspectives reinforced the excitement around advancing less invasive, more accessible approaches to disease monitoring.

Thank you to everyone who stopped by, shared insights, and engaged with us throughout the meeting. We're excited to continue the conversation and help advance the future of blood-based MRD in MM.

#EHA2026 #MultipleMyeloma #MRD #BloodBasedMRD #Hematology #MMSM #MM

[EasyM: Blood-based MRD for MM @easym_test]

What a great first day at EHA 2026!

We really enjoyed all the conversations today and want to thank everyone who took the time to meet with us and discuss blood-based MRD in multiple myeloma.

We're excited for more great discussions tomorrow, and for the first of our two poster sessions! 🎉

If you'll be at EHA, come say hello, stop by our poster, or send us a DM. We'd love to continue the conversation around MRD, disease monitoring, and the evolving landscape of MM care.

See you tomorrow!

#EHA2026 #MultipleMyeloma #MRD #BloodBasedMRD #Hematology #easyM

[EasyM: Blood-based MRD for MM @easym_test]

EHA 2026 is fast approaching!

We're excited to meet colleagues, collaborators, and new connections, and we're looking forward to talking all things blood-based MRD in multiple myeloma.

Stop by our posters (PF833 & P194) or send us a DM to set up a time to connect. We'd love to discuss MRD monitoring, M-protein dynamics, and the latest advances in multiple myeloma research.

See you at EHA!

#EHA2026 #MultipleMyeloma #MRD #BloodBasedMRD #Hematology #CART #MMSM

[European Hematology Association @EHA_Hematology]

Congress registrants should now have received personalized links to access the EHA2026 Congress platform/App. Make sure to complete your profile in order to watch sessions online or on-demand, receive program recommendations, and chat with fellow delegates.

💻 Laptop: Click the link from your email - it opens directly in your browser (Chrome recommended).

📱 Mobile: Tap the link - the Congress App will open if installed, or you’ll be prompted to download it for the best experience.

[EasyM: Blood-based MRD for MM @easym_test]

Heading to EHA? So are we!

We're excited to be presenting two posters at EHA 2026:

📌 PF833 | Poster Session 1
Comparison of Clonotypic Peptide (EasyM) and Intact Immunoglobulin (Exent) Monitoring
🔗https://t.co/coTrIJAg0W

📌 PS1904 | Poster Session 2
Evaluation of Early M-Protein Kinetics Post-CAR T-Cell Therapy with EasyM
🔗https://t.co/N6WM87HSUX

If you're attending EHA, we'd love to connect. Send us a DM or stop by our posters in Hall A to chat about EasyM, MRD monitoring, and multiple myeloma research.

#EHA2026 #MultipleMyeloma #CART #MRD #Hematology #MMSM

[International Myeloma Foundation @IMFmyeloma]

Today is World Blood Cancer Day. Multiple myeloma & other blood cancers affect thousands of families every day. Awareness drives earlier detection, better treatments, & stronger support for patients & care partners. Learn more at https://t.co/szktcXlFue #WorldBloodCancerDay #WBCD

[EasyM: Blood-based MRD for MM @easym_test]

Today is World Blood Cancer Day ❤️

Did you know? Every 27 seconds, someone around the world is diagnosed with blood cancer.

At EasyM, we recognize the importance of awareness, early detection, and accessible healthcare in helping patients receive timely care and support. Today, we stand with patients, families, caregivers, and healthcare professionals in the fight against myeloma and other blood cancers.

Together, through awareness and innovation, we can help create a healthier future for everyone.

#WorldBloodCancerDay #EasyM #BloodCancerAwareness #HealthcareInnovation #CancerAwareness #HopeAndSupport #Myeloma #MM #MRD #MMSM

[EasyM: Blood-based MRD for MM @easym_test]

The EasyM Team is Heading to ASCO 2026! ✈️💼

The countdown is on! The EasyM team is packing our bags and heading to Chicago for the ASCO Annual Meeting!

We are incredibly excited to immerse ourselves in the groundbreaking science, clinical breakthroughs, and vital discussions shaping the future of cancer care worldwide. Above all, we want to connect with the incredible community of clinicians, researchers, innovators, and advocates working to improve patient outcomes.

If you are attending in person, let's make time to connect! We would love to discuss how we can collaborate, share insights, and continue driving meaningful progress in Multiple Myeloma.

📅 When: May 29 - June 2, 2026

📍 Where: McCormick Place | Chicago, IL
👇 Attending #ASCO26? Drop a comment below, or send us a DM to set up a meet-up! See you in Chicago! 🤝

#ASCO26 #EasyM #MultipleMyeloma #MM #MRD #MinimalResidualDisease #PRD

[EasyM: Blood-based MRD for MM @easym_test]

MRD Response: Why Durability Matters More Than Speed

📰New data from the NICHE study (1,048 patients) suggests that when it comes to Minimal Residual Disease (MRD), the speed of your response may be less important than its durability.

Key Findings:

- The "Late + Durable" Advantage: Patients who took longer than 6 months to reach their best response often had better long-term survival than "early responders."
- Duration is Key: Maintaining a stable response for 36+ months was a stronger predictor of success than hitting "MRD Negative" early on.
- Stable is Successful: Even patients who remained "persistent MRD positive" saw excellent outcomes if their disease burden stayed low and stable over time.
- Overcoming High Risk: A durable response helped "cancel out" adverse features, such as high-risk cytogenetics or skipping a transplant.

This study highlights the value of longitudinal monitoring, tracking your personal trends over years, not just months. Read the full article here: https://t.co/LbzJWIrl90

Follow along for the latest updates in MRD research 📢

#MultipleMyeloma #MM #MRD #Hematology #MMSM #PatientAdvocacy

[EasyM: Blood-based MRD for MM @easym_test]

Standard vs. MRD Monitoring: A Deep Dive into M-Protein Testing 🩸

Standard Laboratory Monitoring (SPEP/IFE):

- Clinical standards used to measure monoclonal protein (M-protein) levels.
- These tests analyze the overall distribution of proteins to identify an M-protein "spike."
- Effective at identifying high levels of disease, these tests have a defined "Limit of Detection." Once protein levels decrease below this threshold, they may be unable to distinguish the M-protein from normal, healthy proteins.
- A "not detected" result indicates a significant clinical response, though it does not always confirm the absence of disease at a molecular level.

Minimal Residual Disease Monitoring (Mass Spectrometry):

- Used in specific clinical contexts to achieve higher levels of sensitivity.
- This approach identifies the unique "fingerprint" of a patient’s specific M-protein.
- By focusing on this specific sequence, the laboratory can distinguish the M-protein from background proteins, allowing for the identification of residual disease even when levels are below the detection limit of conventional methods.

#MultipleMyeloma #MM #MMSM #MinimalResidualDisease #Oncology #Hematology #MRD #PatientEducation

[EasyM: Blood-based MRD for MM @easym_test]

Understanding Blood Based MRD Monitoring in Multiple Myeloma 🩸

Check out this @HealthTree Foundation webinar recording featuring @bdermanmd 👇

Dr. Benjamin Derman provides an excellent breakdown of blood based minimal residual disease (MRD) testing in multiple myeloma (MM). Watch the recording to get a better understanding of how these non-invasive alternatives are evolving in MM care.

Link: https://t.co/21Zx8CMeQi

#MultipleMyeloma #MM #MRD #PatientEducation #MyelomaCare #BloodTest #MMSM